PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15922853-1	2005	Receptor tyrosine kinase (RTK) targeted agents such as trastuzumab, imatinib, bevacizumab, and gefitinib inhibitors have illustrated the utility of targeting this protein class for treatment of selected cancers.	Gefitinib	95-104	ret proto-oncogene	Homo sapiens	0-24	
15922853-1	2005	Receptor tyrosine kinase (RTK) targeted agents such as trastuzumab, imatinib, bevacizumab, and gefitinib inhibitors have illustrated the utility of targeting this protein class for treatment of selected cancers.	Gefitinib	95-104	ret proto-oncogene	Homo sapiens	26-29	
30101528-4	2018	Traditional chemotherapy is marginally effective against this form, and erlotinib and gefitinib were introduced as first-line treatments based on the observation that the epidermal growth factor receptor (EGFR), a receptor tyrosine kinase (RTK), is mutated in several cases and, thus, represents a druggable target.	Gefitinib	86-95	ret proto-oncogene	Homo sapiens	214-238	
30101528-4	2018	Traditional chemotherapy is marginally effective against this form, and erlotinib and gefitinib were introduced as first-line treatments based on the observation that the epidermal growth factor receptor (EGFR), a receptor tyrosine kinase (RTK), is mutated in several cases and, thus, represents a druggable target.	Gefitinib	86-95	ret proto-oncogene	Homo sapiens	240-243	
27873490-8	2017	Reversible EGFR-TKI (gefitinib) resensitized cancer cells to RET inhibitors, even in the presence of EGF.	Gefitinib	21-30	ret proto-oncogene	Homo sapiens	61-64	
20701442-4	2010	Additional studies in non-small-cell lung cancer have suggested that the k-ras mutation may be a negative predictor of response to the EGF receptor tyrosine kinase inhibitors erlotinib and gefitinib.	Gefitinib	189-198	ret proto-oncogene	Homo sapiens	139-163